Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4107 | Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 Wiki | 1.00 |
| drug4004 | Three doses of placebo at the schedule of day 0, 14, 28（high-dose group） Wiki | 1.00 |
| drug4003 | Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28 Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4118 | Two doses of placebo at the schedule of day 0, 28（middle-dose group） Wiki | 1.00 |
| drug4112 | Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 Wiki | 1.00 |
| drug4117 | Two doses of placebo at the schedule of day 0, 28（high-dose group） Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
COVID-19 as a novel disease, different disease patterns were observed worldwide, and many treatment plans were tried. So, it is important to investigate the Egyptian clinical characteristics and different factors that determine the patient's 'outcome
Description: Recovery defined as resolution of fever without the use of antipyretics, improvement of respiratory symptoms (e.g., cough, dyspnea) and no need for supplemental oxygen
Measure: Recovery Time: Until patient is discharged or up to 12 weeks whichever comes firstDescription: All cause mortality
Measure: Mortality Time: Until patient is discharged or up to 12 weeks whichever comes firstDescription: Detected by Polymerase Chain Reaction (PCR) test for nasopharyngeal swab
Measure: Conversion of nucleic acid testing for SARS-CoV-2 from positive to negative. Time: Until patient is discharged or up to 12 weeks whichever comes firstDescription: detected by measuring the extent of pulmonary lesion in high resolution computed tomography (HRCT) of the chest
Measure: Radiological progression of the COVID 19 disease Time: Until patient is discharged or up to 12 weeks whichever comes firstDescription: increase oxygen demands detected by arterial blood gases analysis and/or pulse oximeter
Measure: Functional progression of the COVID 19 disease Time: Until patient is discharged or up to 12 weeks whichever comes firstAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports